GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Forward PE Ratio

Argent Biopharma (LSE:RGT) Forward PE Ratio : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma Forward PE Ratio?

Argent Biopharma's Forward PE Ratio for today is 0.00.

Argent Biopharma's PE Ratio without NRI for today is 0.00.

Argent Biopharma's PE Ratio (TTM) for today is 0.00.


Argent Biopharma Forward PE Ratio Historical Data

The historical data trend for Argent Biopharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Forward PE Ratio Chart

Argent Biopharma Annual Data
Trend 2022-04
Forward PE Ratio
14.16

Argent Biopharma Semi-Annual Data
2022-03
Forward PE Ratio 15.63

Competitive Comparison of Argent Biopharma's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Forward PE Ratio falls into.



Argent Biopharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Argent Biopharma  (LSE:RGT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Argent Biopharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.